NO20091675L - Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer - Google Patents

Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer

Info

Publication number
NO20091675L
NO20091675L NO20091675A NO20091675A NO20091675L NO 20091675 L NO20091675 L NO 20091675L NO 20091675 A NO20091675 A NO 20091675A NO 20091675 A NO20091675 A NO 20091675A NO 20091675 L NO20091675 L NO 20091675L
Authority
NO
Norway
Prior art keywords
ht2a
receptors
drug
ether derivative
based double
Prior art date
Application number
NO20091675A
Other languages
English (en)
Norwegian (no)
Inventor
Luca Claudio Gobbi
Olivier Roche
Georg Jaeschke
Rosa Maria Rodriguez Sarmiento
Lucinda Steward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38962066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091675(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091675L publication Critical patent/NO20091675L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20091675A 2006-10-31 2009-04-28 Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer NO20091675L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123274 2006-10-31
PCT/EP2007/061253 WO2008052899A1 (en) 2006-10-31 2007-10-22 Ether derivatives dual modulators of the 5-ht2a and d3 receptors

Publications (1)

Publication Number Publication Date
NO20091675L true NO20091675L (no) 2009-05-28

Family

ID=38962066

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091675A NO20091675L (no) 2006-10-31 2009-04-28 Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer

Country Status (18)

Country Link
US (1) US7795437B2 (zh)
EP (1) EP2079693B1 (zh)
JP (1) JP5087631B2 (zh)
KR (1) KR101114651B1 (zh)
CN (1) CN101535258B (zh)
AR (1) AR063438A1 (zh)
AU (1) AU2007316249B2 (zh)
BR (1) BRPI0718127A2 (zh)
CA (1) CA2667511A1 (zh)
CL (1) CL2007003110A1 (zh)
ES (1) ES2401663T3 (zh)
IL (1) IL198157A0 (zh)
MX (1) MX2009004615A (zh)
NO (1) NO20091675L (zh)
PE (1) PE20081342A1 (zh)
RU (1) RU2009116509A (zh)
TW (1) TW200826940A (zh)
WO (1) WO2008052899A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5502733B2 (ja) * 2007-07-26 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ２ａ及びｄ３受容体の二重のモジュレーター
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024264A (en) * 1974-08-15 1977-05-17 Ab Ferrosan Diphenylbutylpiperidines
GB1514718A (en) 1974-08-15 1978-06-21 Ferrosan Ab Diphenyl-butylpiperidines
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
EP0479601B1 (en) 1990-10-05 1999-12-15 Ajinomoto Co., Inc. Piperidine derivatives and their use as antiarrhythmic agents
US6518286B1 (en) 1999-03-26 2003-02-11 Astrazeneca Ab Compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2254772T3 (es) 2001-12-04 2006-06-16 Actelion Pharmaceuticals Ltd. 4-(piperidil-y pirrolidil-alquil-ureido)-quinoleinas como receptores antagonistas de urotensina ii.
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
AU2003303678A1 (en) 2003-01-03 2004-08-10 Genzyme Corporation Urea derivatives and their use as anti-inflammatory agents
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
RU2009116509A (ru) 2010-12-10
MX2009004615A (es) 2009-05-22
TW200826940A (en) 2008-07-01
KR101114651B1 (ko) 2012-06-12
KR20090075848A (ko) 2009-07-09
WO2008052899A1 (en) 2008-05-08
EP2079693B1 (en) 2013-02-27
AU2007316249B2 (en) 2013-01-24
ES2401663T3 (es) 2013-04-23
CN101535258A (zh) 2009-09-16
US7795437B2 (en) 2010-09-14
CN101535258B (zh) 2012-12-05
US20080103174A1 (en) 2008-05-01
PE20081342A1 (es) 2008-09-18
CL2007003110A1 (es) 2008-06-13
JP5087631B2 (ja) 2012-12-05
AU2007316249A1 (en) 2008-05-08
CA2667511A1 (en) 2008-05-08
JP2010508319A (ja) 2010-03-18
BRPI0718127A2 (pt) 2014-02-18
IL198157A0 (en) 2009-12-24
AR063438A1 (es) 2009-01-28
EP2079693A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
NO20091675L (no) Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
WO2009123714A3 (en) Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009100936A3 (de) Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE523510T1 (de) Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
WO2009065922A3 (de) Organische verbindungen
NO20063602L (no) Benzyl(iden)-laktam-derivater
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
MX2011008336A (es) Derivados de dihidroquinolinona.
NO20091782L (no) Fremgangsmate for syntese av derivater av 3-amino-tetrahydrofuran-3-karboxylsyre og deres anvendelse som medikamenter
WO2007150010A3 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
MX2010001195A (es) Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3.
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
ATE524451T1 (de) Substituierte n-benzo ädü isoxazol-3-yl-amin- derivative als inhibitoren von mglur5, serotonin- (5-ht) und noradrenalin rezeptoren und deren verwendung zur herstellung von arzneimitteln
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
ATE443707T1 (de) Isoxazolin-indol-derivate mit verbesserter antipsychotischer und anxiolytischer aktivität
NO20092400L (no) 4-(Heterocyclyl)Alkyl-N-(Arylsulfonyl) indole compounds and their use as 5-HT6 Ligands

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application